Contact Us
join our enewsletter  |   translate
Donate
Print Page    A A

BBT-877

Status
Phase 1
Condition
Idiopathic Pulmonary Fibrosis
Intervention Type
Oral Drug
Funder Type
Industry

Drug Details

BBT-877 is a potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis.

Study Purpose

This clinical trial is the first-in-human study of BBT-877. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-877 in healthy adult subjects.

Find a Clinical Trial

Latest News on BBT-877

 

footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >


The Pulmonary Fibrosis Foundation rates among top charities in the U.S. The PFF has a three-star rating from Charity Navigator and is a Better Business Bureau accredited charity. The Foundation has met all of the requirements of the National Health Council Standards of Excellence Certification Program®.

Charity Navigator Logobetter business bureau logo NHCSEP_PFF Giving Star

PRIVACY POLICY    TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation   |   230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741   |   f. 866.587.9158   |   info@pulmonaryfibrosis.org
Website created by KlearSky
Join Our Monthly eNewsletter

PRIVACY POLICY    TERMS OF USE

© 2019 Pulmonary Fibrosis Foundation   |   230 East Ohio Street, Suite 500, Chicago, Illinois 60611

p. 888.733.6741   |   f. 866.587.9158   |   info@pulmonaryfibrosis.org
Website created by KlearSky

Join Our Monthly eNewsletter
Subscribe to receive the most current news and updates from the Pulmonary Fibrosis Foundation.